BRIEF-Savara Announces Expanded Access Program For Molgramostim Inhalation Solution For Patients With Autoimmune Pulmonary Alveolar Proteinosis

Reuters
2024-09-27

Sept 27 (Reuters) - Savara Inc :

* SAVARA ANNOUNCES EXPANDED ACCESS PROGRAM (EAP) FOR MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) FOR PATIENTS WITH AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP)

* SAVARA : SAVARA EARLY ACCESS ACCEPTING REQUESTS FROM PATIENTS IN SELECT COUNTRIES IN N.AMERICA & EUROPE, PLANS TO EXPAND THROUGH 2026

* SAVARA INC: PLANS TO COMPLETE SUBMISSION OF A BLA TO FDA FOR MOLGRAMOSTIM IN APAP IN H1 OF 2025

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10